XTSXMDX
Market cap21mUSD
Oct 20, Last price
0.12CAD
Name
Medx Health Corp
Chart & Performance
Profile
MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 456 -10.68% | 511 -9.32% | |||||||
Cost of revenue | 3,070 | 3,894 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,614) | (3,384) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,269 | ||||||||
Tax Rate | |||||||||
NOPAT | (2,614) | (4,653) | |||||||
Net income | (4,581) -10.77% | (5,134) -3.57% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 413 | 20 | |||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 4,962 | 4,120 | |||||||
Long-term debt | 972 | 967 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1 | ||||||||
Net debt | 5,796 | 4,945 | |||||||
Cash flow | |||||||||
Cash from operating activities | (3,422) | (2,801) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 3,418 | 2,837 | |||||||
FCF | (3,405) | (3,619) | |||||||
Balance | |||||||||
Cash | 138 | 142 | |||||||
Long term investments | |||||||||
Excess cash | 115 | 117 | |||||||
Stockholders' equity | (23,898) | (17,927) | |||||||
Invested Capital | 22,600 | 15,205 | |||||||
ROIC | |||||||||
ROCE | 201.42% | 124.33% | |||||||
EV | |||||||||
Common stock shares outstanding | 196,708 | 183,742 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (2,562) | (3,332) | |||||||
EV/EBITDA | |||||||||
Interest | 2,150 | 1,269 | |||||||
Interest/NOPBT |